February 13, 2017 10:40 AM ESTUpdated 11:18 AM
News Briefing

On a shop­ping spree, Al­ler­gan bags CoolSculpt­ing tech in $2.5B buy­out; Ake­bia strikes re­search deal with J&J

Shehla Shakoor

Managing Director

• Botox-mak­er Al­ler­gan has bagged a new com­pa­ny for its med­ical aes­thet­ics port­fo­lio, pay­ing $2.47 bil­lion for Pleasan­ton, CA-based Zel­tiq Aes­thet­ics $ZLTQ. Zel­tiq made …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times